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Objectives: Resistance to extended-spectrum cephalosporins (ESCs) in Escherichia coli can be due to the produc-
tion of ESBLs, plasmid-mediated AmpCs (pAmpCs) or chromosomal AmpCs (cAmpCs). Information regarding type
and prevalence ofb-lactamases, clonal relations and plasmids associated with the blagenes for ESC-R E. coli (ESC-
R-Ec) detected in Switzerland is lacking. Moreover, data focusing on patients referred to the specialized outpatient
clinics (SOCs) are needed.
Methods:We analysed 611 unique E. coli isolated during September–December 2011. ESC-R-Ecwere studied with
microarrays, PCR/DNA sequencing forblaESBLs, blapAmpCs, promoter region ofblacAmpC, IS elements, plasmid incom-
patibility group, and also implementing transformation, aIEF, rep-PCR and MLST.
Results: The highest resistance rates were observed in the SOCs, whereas those in the hospital and community
were lower (e.g. quinolone resistance of 22.6%, 17.2% and 9.0%, respectively; P¼0.003 for SOCs versus commu-
nity). The prevalence of ESC-R-Ec in the three settings was 5.3% (n¼11), 7.8% (n¼22) and 5.7% (n¼7), respect-
ively. Thirty isolates produced CTX-M ESBLs (14 were CTX-M-15), 5 produced CMY-2 pAmpC and 5 hyper-expressed
cAmpCs due to promoter mutations. Fourteen isolates were of sequence type 131 (ST131; 10 with CTX-M-15).
blaCTX-M and blaCMY-2 were associated with an intact or truncated ISEcp1 and were mainly carried by IncF, IncFII
and IncI1plasmids.
Conclusions:ST131 producing CTX-M-15 is the predominant clone. The prevalence of ESC-R-Ec (overall 6.5%) is low,
but an unusual relatively high frequencyof AmpC producers (25%) was noted. The presence of ESC-R-Ec in the SOCs
and their potential ability to be exchanged between hospital and community should be taken into serious consid-
eration.
Keywords: ESBL, AmpC, CMY, CTX-M, ST131
Introduction
Extended-spectrum cephalosporin-resistant Escherichia coli
(ESC-R-Ec) isolates are dramatically increasing worldwide. This
phenomenon is usually due to the production of extended-
spectrum b-lactamases (ESBLs), plasmid-mediated AmpC
(pAmpCs) or, more rarely, chromosomal AmpC (cAmpC).1
Several sequence types (STs) of ESC-R-Ec (e.g. ST131 producing
the CTX-M-15 ESBL) have shown the ability to cause severe infec-
tions in both hospitalized and community patients.1 – 3 However,
data describing the rates and characteristics of ESC-R-Ec in
the community are still limited and, more importantly, those
specifically focusing on the subgroup of patients referring to the
specialized outpatient clinics (SOCs) are almost lacking.2,4,5 In
Switzerland, several works have described the prevalence and
molecular characteristics of ESC-R-Ec detected in healthy people,
food and animals.1,6,7 However, there is a lack of contemporary
data regarding the ESC-R-Ec causing infections in humans.8
Materials and methods
Clinical isolates and definitions
All E. coli identified at the Laboratory of Clinical Microbiology of the University
of Bern (Switzerland) between 1 September and 31 December 2011 were
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analysed. The laboratory receives samples from outpatients and those hos-
pitalizedat theUniversityHospitalofBern(Inselspital).Dataregardingoutpa-
tients were further stratified as ‘community’—patients referring to primary
care general physicians (GPs) and emergency departments (ERs)—and
‘SOCs’—patients referring to the specialized departments of Inselspital. We
defined ‘community acquired’ (CA) and ‘healthcare associated infections’
(HCA) according to the current CDC criteria.9
Species identification and antimicrobial susceptibility
tests (ASTs)
Species identification was achieved by implementing standard biochemical
tests. ASTs were routinely assessed using the disc diffusion method and
results were interpreted according to the CLSI criteria.10 The MICs for differ-
ent antibiotics were obtained in Mueller–Hinton II broth (BBL, Becton Dick-
inson) using the microdilution Sensititre ESB1Fplates (Trek Diagnostics) only
for the ESC-R-Ec (Table S1, available as Supplementary data at JAC Online).
Characterization of b-lactamases
The CT103 microarray (Check-Points) was used to screen the ESC-R-Ec for
the presence of b-lactamase genes. PCR/DNA sequence analyses for the
bla genes found with the microarray were performed as previously
reported.11 BlaOXA-types, the promoter region of blacAmpC and the presence
of ISEcp1-like and ISCR1 genes were also analysed.8,12,13 Production of
b-lactamases was determined using analytical isoelectric focusing (aIEF).6
Analysis of clonality
The ST was obtained using multilocus sequence typing (MLST) Achtman
scheme (http://mlst.ucc.ie/mlst/dbs/Ecoli). Repetitive extragenic palin-
dromic PCR (rep-PCR) and phylogenetic group characterization were also
implemented.6,11
Plasmid analysis
The incompatibility group (Inc) of the plasmid(s) was characterized using a
multiplex PCR (PBRT Kit, Diatheva). Plasmid extract was electroporated into
ElectroMAX E. coli DH10B (Invitrogen) and cells were selected on Luria–
Bertani plates with ampicillin (20 mg/L) or cefotaxime (1 mg/L) (Sigma).
Results and discussion
Six-hundred-and-eleven unique E. coli were analysed. The overall
resistance rates to trimethoprim/sulfamethoxazole, quinolones,
gentamicin and amoxicillin/clavulanate were 31.5%, 17.4%, 19%
and 31.5%, respectively (Table S2, available as Supplementary
data at JAC Online).
The highest resistance rates were observed in the SOCs, whereas
those recorded in hospital and community settings were lower.
For instance, rates to quinolones were 22.6%, 17.2% and 9.0%, re-
spectively (P¼0.003 for SOCs versus community), whereas those
for amoxicillin/clavulanate were 35.1%, 32.3% and 23.8%, respect-
ively (P¼0.04 for SOCs versus community) (Table S3, available as
Supplementary data at JAC Online). Thus, the resistance rates in
SOCs are more similar to those observed in hospital rather than in
the community. The specific use of antibiotics in this setting may
be one of the reasons related to this phenomenon. Unfortunately,
in most institutions like ours, statistics regarding the consumption
of antimicrobials in SOCs are merged with those of the corresponding
hospital wards, making their interpretation in a context of antibiotic
resistance difficult. However, we note that 8 of 11 ESC-R-Ec found in
SOCs were from patients referring to nephrology or urology SOCs
(Figure 1). During the same period of our analysis, these two wards
showed the highest consumption of quinolones [10.7 and 13.3
defined daily doses (DDD)/100 occupied bed-days (BDs), respective-
ly] (Table S4, available as Supplementarydataat JACOnline), a recog-
nized risk factor responsible for selection of ESC-R-Ec.2,3,14
Impact of ESC-R-Ec in the different settings
The overall prevalence of ESC-R-Ec (n¼40; 6.5%) recorded in our
area suggests that the impact of such pathogens is still small com-
pared with other countries.15 However, the analogous prevalence
of ESC-R-Ec observed in the community (n¼7; 5.7%), SOCs
(n¼11; 5.3%) and hospital (n¼22; 7.8%) settings drives further
conclusions (Table S2, available as Supplementary data at JAC
Online).
The relatively low hospital prevalence observed may be justified
by the different standards of hospital infection control pro-
grammes in Switzerland. In contrast, available studies with
which to compare our results about the community and SOCs
are scarce. In fact, most surveys considered invasive nosocomial
infections, whereas studies regarding non-hospitalized patients
are limited.3,4,15 A general prevalence of 1%–4% among outpati-
ents was recorded, but only a few analyses addressed the specific
impact of ESC-R-Ec among GP and ER patients.5,16,17 The preva-
lence of ESC-R-Ec in women with urinary tract infections (UTIs) re-
ferring to GPs was 1% in the Netherlands (2009) and 10% in China
(2004), whereas one study from the USA (2008) reported a fre-
quency of 1% among ER patients.5,18,19 In our area (2008–09),
ESC-R-Ec represented 1.7% of UTIs due to E. coli in community.20
Therefore, the prevalence recorded in the present study (4.2% in
urine in 2011; Table S2, available as Supplementary data at JAC
Online) indicates that there may be a more significant expansion
of ESC-R-Ec in the community than in hospital.
Data about ESC-R-Ec in the SOC setting are essentially unavail-
able because results are frequently merged with those of GPs
and/or ERs.3,14 However, Qi et al.5 reported ESBL-producing E. coli
(ESBL-Ec) in 1% of urine samples collected in SOCs, whereas Doi
et al.2 noted that 33.6% of CA and 22.8% of HCA infections due
to ESC-R-Ec occurred in this setting. In this pilot work we explored
this location, suggesting its possible key role in the spread of
ESC-R-Ec. As shown in Figure 1, 10 of 11 SOC patients (mean age
53.5 years) had a CA infection usually involving the genitourinary
tract (these subjects were referring to the ambulatories of
urology, nephrology or gynaecology). Of note, seven patients had
been hospitalized during the previous year. Moreover, most of
them were referred to the SOCs for many years and had clinical
samples positive for ESC-R-Ec for long periods previously and/or
later than those analysed in the present study (data not shown).
Overall, these figures indicate that SOC patients may serve as a
source amplifying the spread of ESC-R-Ec between hospital and
community settings. In this context, we note that transmission
of ESC-R-Ec from colonized people previously hospitalized to
healthy subjects can occur in the community.11
Molecular characteristics of the ESC-R-Ec
Thirty (75%) ESC-R-Ec were CTX-M-15 (n¼14), CTX-M-27 (n¼7),
CTX-M-1 (n¼5), CTX-M-14 (n¼3) or CTX-M-79-like (n¼1) produ-
cers. The blaCTX-M were carried by IncF/FII plasmids and were
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Isolate ST/main bla gene Age/Sex Infection Acquisition Ward Previously hospitalized (last year)
1
0
0
5
0
4810.28
4810.14
4808.28
4902.33
4809.08
4809.61
4807.55
4812.41
4902.09
4807.33
4806.54
4904.60
4901.67
4812.17
4809.09
4904.36
4812.72
4807.68
4904.50
4901.68
4807.21
4807.06
4807.08
4902.72
4901.66
4903.14
4808.15
4808.13
4901.28
4904.07
4901.09
4809.34
4901.44
4809.24
4902.61
4811.56
4905.17
4903.36
4902.63
4903.72
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ST617/CTX-M-27
ST405/CMY-2, CTX-M-15
ST354/CMY-2
ST648/CTX-M-27
ST648/CTX-M-15
ST648/cAmpC
ST69/CMY-2
ST648/CTX-M-27
ST23/CTX-M-79-like
ST156/cAmpC
ST156/CTX-M-15
ST101/cAmpC
ST1431/CMY-2
ST410/cAmpC
ST1196/CTX-M-1
ST744/CTX-M-14
ST744/CMY-2
ST167/CTX-M-1
ST95/CTX-M-27
ST10/CTX-M-1
ST10/CTX-M-15
ST315/CTX-M-14
ST10/CTX-M-1
ST453/CTX-M-1
ST131/CTX-M-15
ST131/CTX-M-15
ST131/CTX-M-27
ST131/CTX-M-15
ST131/CTX-M-15
ST131/CTX-M-27
ST131/CTX-M-15
ST131/CTX-M-15
ST131/CTX-M-27
ST131/CTX-M-15
ST131/CTX-M-15
ST131/CTX-M-15
ST131/CTX-M-15
ST131/CTX-M-14
ST501/CTX-M-15
ST88/cAmpC
38/F
81/F
35/F
78/F
79/M
55/M
49/F
71/F
88/F
83/M
67/M
64/F
64/F
68/F
52/F
75/M
62/M
84/F
66/F
74/F
59/F
<1/F
34/M
75/F
61/F
53/F
25/F
56/M
69/F
33/F
66/F
33/F
18/M
57/M
68/M
21/F
47/F
57/F
3/M
5/F
UTI
UTI
Nephrostomy
UTI
Liver drainage
UTI
BSI
UTI
UTI
UTI
UTI
UTI
UTI
UTI
UTI
Peritoneal drainage
Intestinal colonization
UTI
UTI
Abdominal abscess
Liver drainage
UTI
Wound
UTI
UTI
UTI
Cervicitis
BSI
UTI
UTI
UTI
Wound
Wound
Abdominal abscess
BSI
Vulvovaginitis
UTI
UTI
Otitis
UTI
HCA
CA
CA
CA
CA
HCA
CA
CA
CA
CA
HCA
CA
CA
HCA
CA
CA
CA
CA
HCA
CA
HCA
CA
CA
CA
CA
CA
CA
HCA
HCA
CA
HCA
CA
HCA
CA
CA
CA
CA
CA
CA
CA
Urology
Uro-Gynecology
SOC: nephrology
Abdominal surgery
ICU
SOC: pneumology
Emergency
SOC: nephrology
Cardiovascular surgery
SOC: urology
ICU
SOC: urology
SOC: nephrology
ICU
SOC: nephrology
ICU
Medicine
Plastic surgery
Cardiovascular surgery
Emergency
Abdominal surgery
Emergency
Plastic surgery
Uro-Gynecology
SOC: nephrology
Emergency
SOC: gynecology
Abdominal surgery
Gastroenterology
Uro-Gynecology
Medicine
Abdominal surgery
Plastic surgery
Abdominal surgery
Abdominal surgery
SOC: gynecology
Emergency
SOC: urology
Emergency
Emergency
Yes (Urology 1 mo before)
No
Yes (Nephrology 6 mo before)
No
No
Yes (Pneumology/Medicine several times during last 2 y)
No
Yes (Nephrology 5 mo before)
No
Yes (Urology/ICU 10 mo before)
No
Yes (Gynecology 2 mo before)
Yes (Nephrology/Urology 5 mo before)
No
Yes (Abdominal surgery 2 mo before)
Yes (Oncology 4 mo before)
No
No
No
Yes (Abdominal surgery 2 w before)
No
No
Yes (Emergency/Urology 4 mo before)
Yes (Uro-Gynecology 6 and 10 mo before)
No
No
No
No
No
No
No
Yes (Abdominal surgery 2 mo before)
Yes (Orthopedy 2 mo before)
No
No
No
No
No
Yes (Paediatric medicine 6 mo before)
No
Figure 1. Results of rep-PCR and MLST analyses presented along with demographic and clinical data of patients with infection due to ESC-R-Ec (n¼40). ST, sequence type; cAmpC,
chromosomal AmpC; CA, community acquired; HCA, healthcare associated; UTI, urinary tract infection; BSI, bloodstream infection; SOC, specialized outpatient clinic; y, years; mo,
months; w, weeks. The dotted line indicates the cut-off value of ≥85% determining clonality between the isolates. The isolates were mainly responsible for CA UTIs (n¼17) and the
major clones were represented by ST131 (n¼14), ST648 (n¼3) and ST10 (n¼3). Notably, 11 of 40 ESC-R-Ec were detected in SOC patients (of which 8 were referred to nephrology or
urology). Notably, two further patients referred to the emergency room (4807.55 and 4903.72) were actually SOC patients (nephrology).
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Table 1. Molecular characteristics of the 40 ESC-R-Ec isolates detected during the study period
Isolate CT103 microarraya
Molecular characterization
(PCR/DNA sequencing)b,c,d aIEF (+0.2)
Plasmid Inc
group(s)
Phylo
group MLST
Plasmid Inc group
for transformant
4810.28 CTX-M-gr-9, TEMall CTX-M-27, TEM-1, OXA-1-like, DISEcp1 3′ end 8.3, 6.0, 5.4 F, FII A ST617 NP
4810.14 CMY-II, CTX-M-gr-1,
TEMall
CMY-2, CTX-M-15, TEM-1, OXA-1-like, ISEcp1
(for both bla genes)
8.9, 6.0, 5.4 F, FII, I1, X1 D ST405 F, FII, I1e
4808.28 CMY-II CMY-2, OXA-1-like, ISEcp1 9.0, 7.0, 6.2 F, FII, I1, X1 D ST354 F, FII, I1, X1
4902.33 CTX-M-gr-9, TEMall CTX-M-27, TEM-1, OXA-1-like, DISEcp1 3′ end 8.6, 8.1, 5.4 F, FII, X1 D ST648 F, FII
4809.08 CTX-M-gr-I CTX-M-15, OXA-1-like, DISEcp1 3′ end 8.9 F, FII, N, Y D ST648 NP
4809.61 — OXA-1-like, [T/A at -32, G/A at -28, G/A at +34,
C/T at +58]
8.6 F, FII, I1, HI2 D ST648 NP
4807.55 CMY-II, TEMall CMY-2, TEM-1, OXA-1-like, DISEcp1 3′ end 9.0, 6.2, 5.4 F, I2, N, P, X1 D ST69 TNO
4812.41 CTX-M-gr-9, TEMall CTX-M-27, TEM-1, OXA-1-like, DISEcp1 3′ end 8.5, 6.2, 5.4 F, FII, N, X1 D ST648 F, FII
4902.09 CTX-M-gr-I CTX-M-79-like, OXA-1-like, ISEcp1 9.0 F, FII, I1 A ST23 F, FII, I1
4807.33 — OXA-1-like, [C/T at -42, G/A at -18, C/T at -1,
C/T at +58]
9.0 B/O, F, FII, I1, P B1 ST156 NP
4806.54 CTX-M-gr-I, TEMall CTX-M-15, TEM-1, OXA-1-like, DISEcp1 3′ end 8.9, 6.0, 5.4 I2 B1 ST156 NP
4904.60 — OXA-1-like, [C/T -42, G/A -18, C/T -1, C/A +24,
A/G +49, C/T +58]
8.6 — B1 ST101 NP
4901.67 CMY-II, TEMall CMY-2, TEM-1, OXA-1-like, ISEcp1 9.0, 6.0, 5.4 B/O, F, FII, K B1 ST1431 F, FII, K
4812.17 — OXA-1-like, [C/T at -42, G/A at -18, C/T at -1,
C/T at +58]
9.0, 6.0 F, FII A ST410 NP
4809.09 CTX-M-gr-I, TEMall CTX-M-1, TEM-1, OXA-1-like, DISEcp1 3′ end 8.5, 8.1, 6.0, 5.4 F, FII, I1, P, R B1 ST1196 FII, I1
4904.36 CTX-M-gr-9, TEMall CTX-M-14, TEM-1, OXA-1-like, ISEcp1 8.1, 6.0, 5.4 F, FII, I2, X1 A ST744 TNO
4812.72 CMY-II, TEMall CMY-2, TEM-1, OXA-1-like, DISEcp1 3′ end 9.0, 6.0, 5.4 F, FII, I1, X1 A ST744 F, FII, I1, X1
4807.68 CTX-M-gr-I, TEMall CTX-M-1, TEM-1, OXA-1-like, DISEcp1 3′ end 8.9, 6.2, 5.4 F, FII, N, X1 A ST167 F, FII
4904.50 CTX-M-gr-9 CTX-M-27, OXA-1-like, DISEcp1 3′ end 8.4 F, FII, X1 B2 ST95 NP
4901.68 CTX-M-gr-I, TEMall CTX-M-1, TEM-1, OXA-1-like, ISEcp1 8.6, 6.0, 5.4 F, FII, I1, X1 A ST10 TNO
4807.21 CTX-M-gr-I CTX-M-15, OXA-1-like, DISEcp1 3′ end 8.9, 7.9, 6.0 F, FII A ST10 F, FII
4807.06 CTX-M-gr-9, TEMall CTX-M-14, TEM-1, OXA-1-like, ISEcp1 8.1, 7.9, 5.4 F, FII D ST315 NP
4807.08 CTX-M-gr-I, TEMall CTX-M-1, TEM-1, OXA-1-like, ISEcp1 8.4, 6.0 F, FII, I2, X1 A ST10 TNO
4902.72 CTXM-gr-1, TEMall CTXM-gr-1, TEMall, TEM-164R CTX-M-1, TEM-1,
OXA-1-like, DISEcp1 3′ end
5.4 F, FII, N B1 ST453 TNO
4901.66 CTX-M-gr-I, TEMall CTX-M-15, TEM-1, OXA-1-like, ISEcp1 8.6, 5.4 F, FII B2 ST131 NP
4903.14 CTX-M-gr-I, TEMall CTX-M-15, TEM-1, OXA-1-like, ISEcp1 8.9, 5.4 F, FII, I2 B2 ST131 TNO
4808.15 CTX-M-gr-9 CTX-M-27, OXA-1-like, DISEcp1 3′ end 8.2, 6.0 B/O, F, FII B2 ST131 NP
4808.13 CTX-M-gr-I CTX-M-15, OXA-1-like, ISEcp1 8.6, 6.0 B/O, F, FII, X1 B2 ST131 NP
4901.28 CTX-M-gr-I CTX-M-15, OXA-1-like, ND 8.9, 7.6, 6.0 F, FII B2 ST131 NP
4904.07 CTX-M-gr-9 CTX-M-27, OXA-1-like, ND 8.6 F, FII B2 ST131 NP
4901.09 CTX-M-gr-I, TEMall CTX-M-15, TEM-1, OXA-1-like, ISEcp1 8.9, 6.2, 5.4 F, FII, N, Y B2 ST131 NP
4809.34 CTX-M-gr-1 CTX-M-15, OXA-1-like, ISEcp1 9.0, 7.6 F, FII B2 ST131 NP
4901.44 CTX-M-gr-9 CTX-M-27, OXA-1-like, ND 8.2 F, FII B2 ST131 F, FII
4809.24 CTX-M-gr-I CTX-M-15, OXA-1-like, DISEcp1 3′ end 8.9, 7.2, 6.2 F, FII B2 ST131 NP
4902.61 CTX-M-gr-I CTX-M-15, OXA-1-like, DISEcp1 3′ end 8.9, 7.2, 6.2 F, FII, I1 B2 ST131 NP
4811.56 CTX-M-gr-I CTX-M-15, OXA-1-like, ISEcp1 8.9 F, FII B2 ST131 NP
4905.17 CTX-M-gr-1, TEMall CTX-M-15, TEM-1, OXA-1-like, ISEcp1 8.9, 5.4 F, FII, I1 B2 ST131 NP
4903.36 CTX-M-gr-9, TEMall CTX-M-14, TEM-1, OXA-1-like, ISEcp1 8.1, 7.9, 5.4 F, FII, N B2 ST131 F, FII
4902.63 CTX-M-gr-I, TEMall CTX-M-15, TEM-1, OXA-1-like, ISEcp1 8.6, 5.4 B/O, F D ST501 F
4903.72 TEMall TEM-1, OXA-1-like, [C/T at -42, G/A at -18,
C/T at -1, C/T at +58]
9.0, 6.0, 5.4 F, FII, HI2 A ST88 NP
NP, transformation in DH10B E. coli strain not performed; TNO, transformants not obtained; – , negative.
aTEMall indicates narrow-spectrum enzymes (e.g. TEM-1/-2) and that TEM-type ESBLs were not present.
bData in square brackets indicate the nucleotide mutations found in the promoter region of the blacAmpC; results for this analysis are not shown when the
promoter region has a wild-type pattern.
cThe blaOXA gene was only partially sequenced (200 bp).
dISEcp1, the element was upstream of the blagene;DISEcp13′ end, the element was upstream of the bla but partially truncated in its 3′ end (isolates with
DISEcp1 5′ were not found); ND, not determined (i.e. an intact ISEcp1 was detected but its position was undetermined).
eFor strain 4810.14, the obtained transformant carried both blaCTX-M-15 and blaCMY-2.
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associated with an intact or truncated ISEcp1 (Table 1).
BlaCTX-M-15/-14/-27 are the most reported blaESBLs among humans
and their association with ISEcp1 and IncF/FII plasmids is also
common. In contrast, blaCTX-M-1 is frequent in animals and food
products.1 Since this specific bla has been recurrently recorded in
Swiss livestock and in the intestinal tract of healthy people,
further analyses to confirm its possible transmission between
animals and humans should be made.1,6
MLST indicated that ST131, ST648 and ST10 were the most
preponderant among the ESBL-Ec. In particular, ST131 isolates
(10 producing CTX-M-15) were found in community (n¼2),
hospital (n¼8) and SOC (n¼4) settings (Figure 1). These pandemic
clones were responsible for CA infections in all settings, indicating
possible exchange and/or common sources among the different
patient populations.1
Five (12.5%) ESC-R-Ecpossessed theblaCMY-2 associated with an
intact or truncated ISEcp1 (Table 1). These E. coli are important
human pathogens in both community and hospital settings.21 Re-
cently, we also recorded a high prevalence of blaCMY-2 in poultry
and pigs.6,7 In such analyses, this gene was associated to IncI1
plasmids, whereas in the present study further Inc groups (IncF/FII)
were also observed. As for blaCTX-M-1, this may indicate that
human and animal isolates partially share the same plasmids.1
The remaining five isolates were cAmpC hyperproducers due to
mutations (at 232 or 242) located within the promoter region.
These strains are occasionally reported in humans and
animals.1,12 However, most previous studies implemented
methods to detect only the ESBL-Ec, probably underestimating
the impact of these specific ESC-R-Ec.5,8,14
CMY-2- or cAmpC-producing isolates were not clonally related
to each other (Figure 1). However, some of these strains were
from STs also present among the ESBL-Ec (ST648, ST156, ST744).
Therefore, identical genotypes have the ability to acquire different
genetic backgrounds of resistance and have the potential for dis-
semination. Indeed, several of them (ST648, ST405, ST410) are
well recognized pandemic clones that usually carry CTX-M-15.1
More surprising is the fact that most of the AmpC producers
were responsible for infection in SOC patients (Figure 1). It is prob-
able that in this population there are some factors that contribute
to their emergence. For example, in the urology of our institution
there is the highest use of b-lactam/b-lactamase inhibitor combi-
nations (70.0 DDD/100 BDs; Table S4, available as Supplementary
data at JACOnline); moreover, in our region amoxicillin/clavulanate
is more frequently implemented than in other areas.22 These treat-
ments might have some effect in the selection of non-susceptible
strains, such as those producing AmpCs.
Conclusions
This is the first Swiss study analysing contemporary ESC-R-Ec
causing infection in humans. Most ESBL-Ec shared common char-
acteristics with those described in other countries (e.g. high preva-
lence of ST131 producing CTX-M-15). More intriguing is the
observation that common clusters of ESC-R-Ec have spread trans-
versally among different settings. In particular, the SOCs may play
an important role in the expansion of these pathogens because it
involves increasing numbers of at-risk outpatients who are con-
stantly referred to healthcare institutions. Since SOC patients
may serve as a ‘bridge’ that favours the spread of ESC-R-Ec
between the hospital and community (or vice versa), larger
epidemiological studies should be planned to better understand
the impact of such pathogens in this setting.11
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